ATC Group: N07BC01 Buprenorphine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N07BC01 in the ATC hierarchy

Level	Code	Title
`1`	N	Nervous system
`2`	N07	Other nervous system drugs
`3`	N07B	Drugs used in addictive disorders
`4`	N07BC	Drugs used in opioid dependence
`5`	N07BC01	Buprenorphine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
SL	Sublingual	8 mg

Active ingredients in N07BC01

Active Ingredient
Buprenorphine
Buprenorphine is an opioid partial agonist/antagonist which attaches itself to the μ (mu) and κ (kappa) receptors of the brain. Its activity in opioid maintenance treatment is attributed to its slowly reversible link with the μ receptors which, over a prolonged period, minimises the need of illicit opioids for patients with opioid dependence.

Related product monographs

Document	Type	Information Source
BUVIDAL Prolonged-release solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)
ESPRANOR Oral lyophilisate	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
SIXMO Implant	MPI, EU: SmPC	European Medicines Agency (EU)
SUBLOCADE Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
Subutex 2mg sublingual tablets	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)